Abbott CMV diagnostic tie-up a step towards Astellas' 'precision medicine' vision
This article was originally published in Scrip
A collaborative agreement with Abbott Molecular for the use of virus monitoring technology in a Phase III clinical trial with a candidate vaccine for cytomegalovirus (CMV) fits in well with Astellas' stated goal of pursuing "precision medicine".
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context